NewAmsterdam Pharma Company N.V. reported its financial results for the third quarter of 2025, revealing a significant decline in revenue and an increase in operating losses compared to the same period last year. The company generated revenue of $348,000 for the three months ended September 30, 2025, a decrease of 99% from $29.1 million in the same quarter of 2024. This sharp decline was primarily attributed to the absence of clinical development milestone revenue, which had contributed $27.3 million in the prior year. For the nine months ended September 30, 2025, total revenue was $22.5 million, down 31% from $32.8 million in the same period of 2024.
Operating expenses for the third quarter increased slightly to $55.5 million, compared to $54.1 million in the prior year. Research and development expenses decreased to $31.0 million from $35.7 million, reflecting the completion of several Phase 3 clinical trials. However, selling, general, and administrative expenses rose significantly to $24.5 million, up from $18.4 million, driven by increased personnel costs related to share-based compensation and preparations for commercial operations. The company reported an operating loss of $55.1 million for the quarter, compared to a loss of $25.0 million in the same quarter of 2024.
In terms of strategic developments, NewAmsterdam Pharma entered into a Supply Agreement with A. Menarini International Licensing S.A. on August 12, 2025, to provide commercial supply of its product, obicetrapib, for distribution in Europe. This agreement is part of the company's broader strategy to commercialize obicetrapib, which is currently under review by the European Medicines Agency. The company also reported that it had completed the merger of its non-operating subsidiaries, which had no material impact on its financial statements.
As of September 30, 2025, NewAmsterdam Pharma had cash, cash equivalents, and marketable securities totaling $756 million, a decrease from $864.6 million at the end of 2024. The company’s accumulated losses reached $687.5 million, reflecting ongoing investments in research and development. Looking ahead, NewAmsterdam Pharma anticipates continued significant losses as it advances its clinical trials and seeks regulatory approvals for obicetrapib. The company remains focused on its goal of providing effective LDL-C lowering therapies for patients with cardiovascular disease, with plans to commercialize obicetrapib in the U.S. and Europe, pending regulatory approvals.
About NewAmsterdam Pharma Co N.V.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.